Skip to main content
. 2015 Sep;100(9):1214–1221. doi: 10.3324/haematol.2015.124651

Figure 1.

Figure 1.

(A). Time to progression requiring myeloma therapy (TTT). The four-gene score identified a high-risk group with an estimated probability of 2-year progression to myeloma of 85.7%. (B) Limiting the four-gene score to 96 patients with SMM, as defined by the recent International Myeloma Working Group criteria yielded a 2-year risk of treatment of 81.8%. (C). By comparison, the GEP70 identified a high-risk group with an estimated 2-year progression probability of 49.7%